Based on the results, iTeos and GSK are stopping all ongoing trials of belrestotug, including an ongoing Phase 3 study in lung cancer. iTeos is “taking immediate steps to preserve capital” as ...

On July 7, 2025, iTeos Therapeutics, Inc. (NASDAQ:ITOS) stock closed at $10.07 per share, with a market capitalization of $385.417 million.

ITeos may face some questions on the safety of combining the two medicines, which both ramp up the body’s immune attack on tumors. Three patients in the trial died from immune-related ...

“As iTeos reaches a pivotal moment towards recognizing our ambition to become a leading oncology company, we’re excited to welcome Dr. Feltquate as Chief Medical Officer,” said Michel ...

Turning to iTeos Therapeutics' balance sheet, the company had cash and cash equivalents of $216.2M, short-term investments of $383.0M, and long-term investments of $78.3M as of June 30, 2023.

iTeos Therapeutics Price Performance NASDAQ ITOS opened at $7.50 on Friday. The firm has a market capitalization of $286.46 million, a P/E ratio of -2.38 and a beta of 1.43. iTeos Therapeutics has ...

In April, iTeos said its cash and investments position was $624.3 million as of March 31, 2025, which is expected to provide a cash runway into 2027. Price Action: ITOS stock is up 17.3% at $8.12 ...

Biotech iTeos brings on Sanofi cancer VP as CMO as it wades deeper into the clinic By Conor Hale Mar 26, 2019 10:25am chief medical officer clinical research immuno-oncology iTeos Therapeutics ...

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages ...

iTeos Therapeutics has raised $75 million (€64 million) to take two immuno-oncology assets into the clinic. The MPM Capital-led series B tees iTeos up to start dosing patients with an adenosine ...

GSK and iTeos will share in the work and the expenses for global development of EOS-448, according to the agreement. They’ll also share in commercializing the drug—if it’s approved.